Hôpital Max Fourestier?Nan- terrre) ,
Hôpital Foch?Suresnes); Gilles Force (Hôpital du Notre Dame du Perpétuel Secours?Levallois Perret) ,
CH de l'agglomération Mon- targeoise?Amilly?Montargis) ,
); E Lagier (Aix-en-provence); A Vabret (Caen) ,
Rouen); A Signoris-Schmuck (Grenoble) ,
Chalon-sur-soane); AS Poirier (LaRoche-Sur-Yon) ,
Lille); B Chanzy (Pringy); E Schvoerer (Nancy); S Fafi-Kremer (Stras- bourg) ,
Chaumont); N Azencott (Dignes-les-bains) Data management and statistical analysis: A Besseghir ,
Author Contributions Conceived and designed the experiments: BV CC GC. Performed the experiments: GC MB Analyzed the data: Contributed reagents/materials ,
Enfuvirtide, the first fusion inhibitor to treat HIV infection, AIDS Rev, vol.7, pp.139-147, 2005. ,
Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors, Proceedings of the National Academy of Sciences, vol.99, issue.22, pp.14410-14415, 2002. ,
DOI : 10.1073/pnas.222366699
In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors, Antimicrobial Agents and Chemotherapy, vol.52, issue.4, pp.1545-1548, 2008. ,
DOI : 10.1128/AAC.01284-07
URL : https://hal.archives-ouvertes.fr/inserm-00263591
In Vitro Phenotypic Susceptibility of HIV-2 Clinical Isolates to CCR5 Inhibitors, Antimicrobial Agents and Chemotherapy, vol.56, issue.1, pp.137-139, 2012. ,
DOI : 10.1128/AAC.05313-11
Susceptibility of HIV Type 2 Primary Isolates to CCR5 and CXCR4 Monoclonal Antibodies, Ligands, and Small Molecule Inhibitors, AIDS Research and Human Retroviruses, vol.doi, pp.10-10890124, 2011. ,
DOI : 10.1089/aid.2011.0124
Baseline susceptibility of primary HIV-2 to entry inhibitors, Antiviral Therapy, vol.17, issue.3, pp.565-570, 2012. ,
DOI : 10.3851/IMP1996
Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc, Antiviral Research, vol.86, issue.2, pp.224-226, 2010. ,
DOI : 10.1016/j.antiviral.2010.02.324
Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure, Journal of Clinical Virology, vol.47, issue.1, pp.79-81, 2010. ,
DOI : 10.1016/j.jcv.2009.11.008
Long-term maraviroc use as salvage therapy in HIV-2 infection, Journal of Antimicrobial Chemotherapy, vol.67, issue.10, pp.2538-2539, 2012. ,
DOI : 10.1093/jac/dks240
URL : http://jac.oxfordjournals.org/cgi/content/short/67/10/2538
Coreceptor usage by HIV-1 and HIV-2 primary isolates: The relevance of CCR8 chemokine receptor as an alternative coreceptor, Virology, vol.408, issue.2, pp.174-182, 2010. ,
DOI : 10.1016/j.virol.2010.09.020
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage, J Virol, vol.73, pp.2343-2349, 1999. ,
CCR5, GPR15, and CXCR6 Are Major Coreceptors of Human Immunodeficiency Virus Type 2 Variants Isolated from Individuals with and without Plasma Viremia, Journal of Virology, vol.79, issue.3, p.15650194, 2005. ,
DOI : 10.1128/JVI.79.3.1686-1700.2005
A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4, J Virol, vol.72, pp.4065-4071, 1998. ,
CCR5 or CXCR4 Is Required for Efficient Infection of Peripheral Blood Mononuclear Cells by Promiscuous Human Immunodeficiency Virus Type 2 Primary Isolates, AIDS Research and Human Retroviruses, vol.18, issue.3, pp.193-200, 2002. ,
DOI : 10.1089/08892220252781248
Use of Inhibitors To Evaluate Coreceptor Usage by Simian and Simian/Human Immunodeficiency Viruses and Human Immunodeficiency Virus Type 2 in Primary Cells, Journal of Virology, vol.74, issue.15, pp.6893-6910, 2000. ,
DOI : 10.1128/JVI.74.15.6893-6910.2000
Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1???Infected, Treatment-Experienced, CCR5 Antagonist???Naive Subjects, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.57, issue.2, pp.118-125, 2011. ,
DOI : 10.1097/QAI.0b013e318213c2c0
Week 24 Primary Analysis of Cenicriviroc vs Efavirenz, in Combination with FTC/TDF, in Treatment-naïve HIV-1 Infected Adults with CCR5-tropic Virus, 20th Conference on Retroviruses and Opportunistic Infections (CROI), 2013. ,